Actavis plc announced today that it has completed the acquisition of Allergan, Inc. in a cash and equity transaction currently valued at approximately $66bn. The combination creates one of the world’s top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23bn anticipated in 2015.
“The combination of Actavis and Allergan creates an exceptional global pharmaceutical company and a leader in a new industry model – growth pharma,” said Brent Saunders, CEO and president of Actavis.
“Anchored by world-renowned brand franchises, a leading global generics business, a premier pharmaceutical development pipeline and an experienced management team committed to maintaining highly efficient operations across the organisation, we are creating an unrivalled foundation for long-term growth.”
He added: “Our combined company will be built around a customer-focused commitment to partnering with physicians, pharmacists and patients to deliver innovative treatments and enhance access to important therapies around the world. We have industry-leading global commercial strength, with sustainable blockbuster brand franchises in key therapeutic categories and broad commercial reach extending across approximately 100 countries. Our experienced field-based will continue to deliver exceptional support on a broad range of products to physicians and specialists around the world. And our powerful global supply chain is broadly recognised as a world leader, with continued excellence in quality and customer service.
“Supporting the growth of this innovative industry model is our strategically focused R&D engine, built on novel compounds in specialty and primary care markets where there is significant unmet medical need, and fueled with approximately $1.7bn in annual investment. With an innovative product development portfolio exceeding 20 near-term projects and a world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S. and more than 1,000 marketing authorisations globally, we are uniquely positioned within our industry to ensure our development activities support sustainable long-term organic growth.
“With the acquisition now complete, we will immediately begin implementing our comprehensive integration plans to ensure that we leverage our strengthened global organisation to generate sustainable organic earnings growth from our newly expanded base, and continue our ascent into the fastest-growing and most dynamic growth pharmaceutical company in global healthcare.”
Actavis continues to expect the transaction to generate double-digit accretion to non-GAAP earnings within the first 12 months, including approximately $1.8bn in operating and financial synergies to be realised within one year following the close. These synergies exclude any additional revenue or manufacturing synergies, and are in addition to the $475m of annual savings previously announced by Allergan in connection with Project Endurance. Actavis further expects to generate strong operating cash flow in excess of $8bn in 2016, which would enable the company to rapidly de-lever the balance sheet.